Clinical Observation on Combined Chemotherapy with Nedaplatin, Tegafur and Paclitaxel in Advanced Esophageal Carcinoma

Objective: To investigate the efficacy and safety of the chemotherapy regimen with nedaplatin,tegafur and paclitaxel in advanced tesophageal carcinoma.Methods: Sixty-five patients with pathologically confirmed advanced esophageal carcinoma admitted in our hospital from March 2008 to June 2010 were chosen,and were treated with three-week intravenous chemotherapy regimen with NDP 20 mg/m2,d1-d3,Ft-207 500 mg/m2,d1-d5,and PTx 135-175mg/m2,d1.A treatment cycle was 28 days.The Efficacy and toxicity were evaluated after at least 2 treatment cycles.Results: In 65 cases,only one patient had to quit for allergic reaction to NDP in the first cycle,the other sixty-four patients were eligible for clinical response evaluation,in which the overall response rate was 57.8%,the complete remission rate was 4.7%(n=3),the partial remission rate was 51.6%(n=33) and the stable rate was 26.6%(n=17),in addition to 17.2% disease progress(n=11).Only one patient encountered a controllable bone marrow depression of grade IV.Conclusion: The combined chemotherapy with PTX,NDP and Ft-207 is effective and safe in advanced esophageal cancer,and is worth of further generalization.